Profile
Join date: Mar 10, 2022
About

The global scleroderma therapeutics market size was valued at USD 1.60 billion in 2018 and is estimated to expand at a CAGR of 6.0% from 2019 to 2026. The market is mainly driven by the off-label use of drugs approved for its symptomatic indications, such as rheumatoid arthritis. Lack of curative therapies and high prevalence of off-label drug use are underlying factors spurring interest in rare disease markets. This is expected to fuel the development of targeted biologics and small molecule combination therapies. Increasing prevalence of scleroderma and rising incidences of genetic mutations coupled with drastic changes in the environment are also expected to be the key factors driving the market.

smax59551
More actions